These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30592148)

  • 1. Transcriptome analysis of differentially expressed genes and pathways associated with mitoxantrone treatment prostate cancer.
    Li S; Li R; Ma Y; Zhang C; Huang T; Zhu S
    J Cell Mol Med; 2019 Mar; 23(3):1987-2000. PubMed ID: 30592148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of key genes and specific pathways potentially involved in androgen-independent, mitoxantrone-resistant prostate cancer.
    Zhu S; Jiang L; Wang L; Wang L; Zhang C; Ma Y; Huang T
    Cancer Manag Res; 2019; 11():419-430. PubMed ID: 30655694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory effects of antitumor agent matrine on FOXO and PI3K-AKT pathway in castration-resistant prostate cancer cells.
    Li Q; Huang H; He Z; Sun Y; Tang Y; Shang X; Wang C
    Sci China Life Sci; 2018 May; 61(5):550-558. PubMed ID: 29119376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of prostate cancer hub genes and therapeutic agents using bioinformatics approach.
    Fang E; Zhang X; Wang Q; Wang D
    Cancer Biomark; 2017 Dec; 20(4):553-561. PubMed ID: 28800317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of apoptotic pathways in docosahexaenoic acid-induced benefit in prostate cancer: Pathway-focused gene expression analysis using RT
    Sun Y; Jia X; Hou L; Liu X; Gao Q
    Lipids Health Dis; 2017 Mar; 16(1):59. PubMed ID: 28330470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression.
    Li C; Sun H; Wei W; Liu Q; Wang Y; Zhang Y; Lian F; Liu F; Li C; Ying K; Huo H; Qi Z; Li B
    Cell Oncol (Dordr); 2020 Dec; 43(6):1099-1116. PubMed ID: 32710433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and analysis of mRNA, miRNA, lncRNA, and TF regulatory networks reveal the key genes associated with prostate cancer.
    Ye Y; Li SL; Wang SY
    PLoS One; 2018; 13(8):e0198055. PubMed ID: 30138363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
    Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
    JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
    Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KAT5 and KAT6B are in positive regulation on cell proliferation of prostate cancer through PI3K-AKT signaling.
    He W; Zhang MG; Wang XJ; Zhong S; Shao Y; Zhu Y; Shen ZJ
    Int J Clin Exp Pathol; 2013; 6(12):2864-71. PubMed ID: 24294372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA damage induces GDNF secretion in the tumor microenvironment with paracrine effects promoting prostate cancer treatment resistance.
    Huber RM; Lucas JM; Gomez-Sarosi LA; Coleman I; Zhao S; Coleman R; Nelson PS
    Oncotarget; 2015 Feb; 6(4):2134-47. PubMed ID: 25575823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, PI3K/Akt, GSK-3β signaling and inhibition of cellular prostatic acid phosphatase.
    Gesmundo I; Di Blasio L; Banfi D; Villanova T; Fanciulli A; Favaro E; Gamba G; Musuraca C; Rapa I; Volante M; Munegato S; Papotti M; Gontero P; Primo L; Ghigo E; Granata R
    Cancer Lett; 2019 May; 449():252-262. PubMed ID: 30790678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of docetaxel resistance genes in castration-resistant prostate cancer.
    Marín-Aguilera M; Codony-Servat J; Kalko SG; Fernández PL; Bermudo R; Buxo E; Ribal MJ; Gascón P; Mellado B
    Mol Cancer Ther; 2012 Feb; 11(2):329-39. PubMed ID: 22027694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Illumina whole-genome complementary DNA-mediated annealing, selection, extension and ligation platform: assessing its performance in formalin-fixed, paraffin-embedded samples and identifying invasion pattern-related genes in oral squamous cell carcinoma.
    Loudig O; Brandwein-Gensler M; Kim RS; Lin J; Isayeva T; Liu C; Segall JE; Kenny PA; Prystowsky MB
    Hum Pathol; 2011 Dec; 42(12):1911-22. PubMed ID: 21683979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
    Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
    Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of prostate cancer cell transcriptomes in 2D monoculture vs 3D xenografts identify consistent gene expression alterations associated with tumor microenvironments.
    Brady L; Gil da Costa RM; Coleman IM; Matson CK; Risk MC; Coleman RT; Nelson PS
    Prostate; 2020 May; 80(6):491-499. PubMed ID: 32068909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer.
    Liu Z; Zhu G; Getzenberg RH; Veltri RW
    J Cell Biochem; 2015 Jul; 116(7):1341-9. PubMed ID: 25640606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. THBS4 silencing regulates the cancer stem cell-like properties in prostate cancer via blocking the PI3K/Akt pathway.
    Hou Y; Li H; Huo W
    Prostate; 2020 Jul; 80(10):753-763. PubMed ID: 32421868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing TTK expression inhibits the proliferation and progression of prostate cancer.
    Chen S; Wang J; Wang L; Peng H; Xiao L; Li C; Lin D; Yang K
    Exp Cell Res; 2019 Dec; 385(1):111669. PubMed ID: 31605696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.